Winnipeg Free Press - PRINT EDITION

Big Pharma in no rush for Ebola vaccine

  • Print

Ebola is a truly frightening disease, with a fatality rate as high as 95 per cent (although the death rate in the current outbreak in West Africa is only 55 to 60 per cent). At the moment, it is largely confined to a heavily forested inland area where the borders of Liberia, Sierra Leone and Guinea meet, although cases have already appeared in the capital cities of all three countries.

It could get much worse. If Ebola gained a significant foothold in a prosperous, densely populated country such as Nigeria, whose citizens travel all over the world, the current 800 recorded deaths could become 8,000, or 80,000, or even more. And the worst of it is there is no effective vaccine or treatment for Ebola.

Let me rephrase that. There is no APPROVED vaccine or treatment for Ebola. There are candidates, some of which have shown promising results when tested on non-human primates.

But they haven't gone through the full testing process that is necessary before they are approved for human use, because nobody was willing to pay for it.

The normal procedure in the United States, home to more than half the world's major drug companies (Big Pharma), is that basic research for new drugs may be paid for by government grants or even by private philanthropy (such as Bill Gates's $200-million donation for research on a malaria vaccine), but the work of bringing the drugs to market is left to the commercial companies. All too often, they simply can't be bothered.

It costs hundred of millions of dollars to take a drug through the whole approval process and put it on the market. That's worthwhile if the drug will then sell at a high cost and be used regularly over long periods of time: A drug that fights "rich people's diseases" such as cancer or heart disease, say, or even something like Viagra. But a one-shot vaccine that would mainly be used by poor Africans will never make a profit, so it is ignored.

Galvanized by the panic over Ebola, the National Institutes of Health in the United States has now scheduled Phase 1 trials of an Ebola vaccine on human subjects for next month. But there are two more phases after that, and the earliest a vaccine could be approved for general use is next July. And even in this emergency, it's public money, not Big Pharma, that is funding the research.

The problem goes much wider than Ebola and other tropical diseases. It extends, unfortunately, to the antibiotics that vanquished the bacterial infections that were once responsible for about 25 per cent of adult deaths. The last new class of antibiotics, carbapenems, was approved in 1980. Since then, nothing -- even though the usefulness of existing antibiotics is rapidly eroding as resistant strains of bacteria emerge.

That's a big threat, but antibiotics are still not big money-makers, as they are used for relatively short periods of time to fight some specific infection. So no new type of antibiotic has been developed by Big Pharma for more than three decades. A minimum of 23,000 people in the United States died last year of infections that would once have been easily ended by antibiotics; in the European Union the total was 25,000.

There are some measures that would dramatically slow the spread of antibiotic-resistant bacteria. Far fewer prescriptions should be written for antibiotics, and doctors should be monitored to ensure they are not over-prescribing. Patients must complete any course of antibiotics they begin and report they have done so. Over-the-counter sales of antibiotics in countries such as China and Russia must cease.

Above all, it should be a criminal offence to feed antibiotics to animals just to make them grow faster and bigger. (That is where 80 per cent of the antibiotics consumed in the United States go at the moment.) And even when all that has been done, the rise of antibiotic-resistant bacteria will continue, though at a much slower pace. Bacterial resistance is an evolutionary process that can only be slowed, not stopped.

So we desperately need new antibiotics, and there are none forthcoming. Without them, warned Dame Sally Davies, chief medical officer for England, "modern medicine would quickly go out of the window."

Almost all surgery, including things as commonplace as caesarian sections and hip replacements, and most cancer treatments as well, involve a significant risk of infection that must be controlled by antibiotics. As British Prime Minister David Cameron told The Times: "If we fail to act ... we are cast back into the dark ages of medicine, where treatable infections and injuries will kill once again."

Yet Big Pharma will not fill the gap, for those companies are answerable to their shareholders, not to the public. The case for direct state intervention to finance the development of the vaccines and antibiotics the commercial sector neglects is overwhelming. And very urgent.

Gwynne Dyer is an independent journalist whose articles on world affairs are published in 45 countries.

Republished from the Winnipeg Free Press print edition August 8, 2014 A11

Fact Check

Fact Check

Have you found an error, or know of something we’ve missed in one of our stories?
Please use the form below and let us know.

* Required
  • Please post the headline of the story or the title of the video with the error.

  • Please post exactly what was wrong with the story.

  • Please indicate your source for the correct information.

  • Yes

    No

  • This will only be used to contact you if we have a question about your submission, it will not be used to identify you or be published.

  • Cancel

Having problems with the form?

Contact Us Directly
  • Print

You can comment on most stories on winnipegfreepress.com. You can also agree or disagree with other comments. All you need to do is be a Winnipeg Free Press print or e-edition subscriber to join the conversation and give your feedback.

You can comment on most stories on winnipegfreepress.com. You can also agree or disagree with other comments. All you need to do is be a Winnipeg Free Press print or e-edition subscriber to join the conversation and give your feedback.

Have Your Say

New to commenting? Check out our Frequently Asked Questions.

Have Your Say

Comments are open to Winnipeg Free Press print or e-edition subscribers only. why?

Have Your Say

Comments are open to Winnipeg Free Press Subscribers only. why?

The Winnipeg Free Press does not necessarily endorse any of the views posted. By submitting your comment, you agree to our Terms and Conditions. These terms were revised effective April 16, 2010.

letters

Make text: Larger | Smaller

LATEST VIDEO

Sneak peek: MTS Centre’s renovations for 2014/15 season

View more like this

Photo Store Gallery

  • RUTH BONNEVILLE / WINNIPEG FREE PRESS June 23, 2011 Local - A Monarch butterfly is perched on a flower  in the newly opened Butterfly Garden in Assiniboine Park Thursday morning.
  • A nesting goose sits on the roof of GoodLife Fitness at 143 Nature Way near Kenaston as the morning sun comes up Wednesday morning- See Bryksa’s Goose a Day Photo- Day 07- Web crop-May 09, 2012   (JOE BRYKSA / WINNIPEG FREE PRESS)

View More Gallery Photos

Poll

Do you support Canada's involvement in the fight against Islamic State?

View Results

View Related Story

Ads by Google